In vitro antibacterial activity of Men 10700, a new penem antibiotic

Chemotherapy

Volumn 45, Issue 6, 1999, Pages 405-410

  Varotto, Fabio ^a   Parravidini, Elena ^a   De Luca, Massimo ^b   Casini, Alessandro ^b   Fraschini, Franco ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Menarini Ricerche SpA   (Italy)

Author keywords

In vitro activity; Men 10700; Penems

Indexed keywords

2 [[[6 (1 HYDROXYETHYL) 2 METHYL 7 OXO 4 THIA 1 AZABICYCLO[3.2.0]HEPT 2 EN 3 YL]METHYL]METHYLAMINO]ACETAMIDE; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; NEW DRUG; PENEM DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; ENTEROBACTER CLOACAE; ENTEROCOCCUS; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NONHUMAN; PRIORITY JOURNAL; SERRATIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE;

EID: 0032752763     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007233     Document Type: Article

References (14)

1. Neu HC, Chin NX, Labthavikul P: The in-vitro activity of a novel penem FCE 22101 compared to other beta-lactam antibiotics. J Antimicrob Chemother 1985;16:305-313.
2. Nagashima M, Goto S, Yoshida T, Matsunaga T, Shimohira H, Ogawa M: In vitro and in vivo activities of sulopenem compared with those of imipenem and cephalosporins. Jpn J Antibiot 1996;49:303-323.
3. Woodcock JM, Andrews JM, Brenwald NP, Ashby JP, Wise R: The in vitro activity of faropenem, a novel oral penem. J Antimicrob Chemother 1997;39:35-43.
4. Poggesi I, Spinelli R, Frigerio E, Strolin Benedetti M, Carrà L, Sassella D, Rimoldi R: A study of the pharmacokinetics and tolerability of ritipenem acoxil in healthy volunteers following multiple oral dosing. J Antimicrob Chemother 1997;40: 291-294.
5. Swedish Urinary Tract Infection Study Group: Interpretation of the bacteriologic outcome of antibiotic treatment for uncomplicated cystitis: Impact of the definition of significant bacteriuria in a comparison of ritipenem acoxil with norfloxacin. Clin Infect Dis 1995;20:507-513.
6. Wise R, Ballard RC: Review of the in-vitro evaluation of FCE 22101. J Antimicrob Chemother 1989;23 (suppl C):7-16.
7. Di Modugno E, Erbetti I, Ferrari L, Galassi G, Hammond SM, Xerri L: In vitro activity of the tribactam GV104326 against Gram-positive, Gram-negative and anaerobic bacteria. Antimicrob Agents Chemother 1994;38:2362-2368.
8. Wise R, Andrews JM, Brenwald N: In vitro activity of the tricyclic beta-lactam GV 104326. Antimicrob Agents Chemother 1996;40:1248-1253.
9. Altamura M, Perrotta E, Sbraci P, Pestellini V, Arcamone F, Cascio G, Satta G, Morandotti G, Sperning R: Synthesis and antibacterial activity of Men 10700, a new penem antibiotic. Bioorg Med Chem Lett 1995;5: 555-558.
10. Altamura M, Perrotta E, Sbraci P, Pestellini V, Arcamone F: 2-Substituted penems with amino acid-related side chains: Synthesis and antibacterial activity of a new series of beta-lactam antibiotics. J Med Chem 1995;38:4244-4256.
11. Hamilton-Miller JMT, Shah S: In-vitro microbiological assessment of a new penem, Men 10700. J Antimicrob Chemother 1997;39:575-584.
12. Fontana R, Altamura M, Arcamone F, Mazzariol A, Morandotti G, Sperning R, Cornaglia G: Men 10700, a new penem antibiotic: In-vitro activity and its correlation with beta-lactamase stability, PBP affinity and diffusion through the bacterial cell wall. J Antimicrob Chemother 1998;41:513-525.
13. Butler JC, Hofmann J, Cetron MS, Elliott JA, Facklam RR, Breiman RF: The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: An update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect Dis 1996;174:986-993.
14. Adu A, Armour CL: Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime. Drugs 1995;50:423-439.